SCHEMBL5223218

SCHEMBL5223218

COc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 10/20 0.73
NPC1 O15118 4/20 0.72
RAB9A P51151 4/20 0.72
MEN1 O00255 1/20 0.72
POLB P06746 1/20 0.72
KMT2A Q03164 1/20 0.72
ABCG2 Q9UNQ0 1/20 0.70
PPARG P37231 6/20 0.69
PPARA Q07869 5/20 0.69
RXFP1 Q9HBX9 1/20 0.67
PKM P14618 1/20 0.65
TDP1 Q9NUW8 1/20 0.65
TP53 P04637 2/20 0.62
F10 P00742 1/20 0.62
PPARD Q03181 1/20 0.62
GPBAR1 Q8TDU6 1/20 0.62
ALOX15 P16050 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
MAPT P10636 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5226076 0.92 NPC1 (0.71) NR1H4NPC1RAB9AMEN1POLB
SCHEMBL7243018 0.89 NR1H4 (0.72) NR1H4NPC1RAB9AMEN1POLB
SCHEMBL5226517 0.88 NPC1 (0.76) NPC1RAB9AMEN1POLBKMT2A
SCHEMBL5226864 0.87 NR1H4 (0.77) NR1H4PPARGPPARATP53PPARD
SCHEMBL5224977 0.87 NR1H4 (0.69) NR1H4NPC1RAB9AMEN1POLB
SCHEMBL7301192 0.87 NPC1 (0.81) NR1H4NPC1RAB9AMEN1KMT2A
SCHEMBL7304276 0.87 NPC1 (0.81) NR1H4NPC1RAB9AMEN1KMT2A
SCHEMBL5223950 0.86 NR1H4 (0.71) NR1H4NPC1RAB9APPARGPPARA
SCHEMBL29903436 0.86 NR1H4 (0.74) NR1H4PPARGPPARAPPARD
SCHEMBL5222902 0.85 NR1H4 (0.67) NR1H4MEN1POLBKMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 NR1H4 2304/4885NPC1 1618/4885RAB9A 2658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.